TREATMENT FOR VIRAL INFECTION
Provided herein is a leukocyte tyrosine kinase (LTK) inhibitor for use in the treatment of a viral infection in a subject, wherein the viral infection is caused by an RNA virus. Also provided are methods of treating a viral infection in a subject, wherein the viral infection is caused by an RNA virus, the method comprising administering to the subject an LTK inhibitor, and the use of an LTK inhibitor in the manufacture of a medicament for the treatment of a viral infection, wherein the viral infection is caused by an RNA virus. In particular, the infection may be an influenza or coronavirus infection in a human subject..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Europäisches Patentamt - (2023) vom: 09. Aug. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
FARHAN HESSO [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-08-09, Last update posted on www.tib.eu: 2024-01-23, Last updated: 2024-01-26 |
---|
Patentnummer: |
EP4221706 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA017853710 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA017853710 | ||
003 | DE-627 | ||
005 | 20240126101229.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230818s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA017853710 | ||
035 | |a (EPA)EP4221706 | ||
035 | |a (EPA)73223829 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a FARHAN HESSO |e verfasserin |4 aut | |
245 | 1 | 0 | |a TREATMENT FOR VIRAL INFECTION |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2023-08-09, Last update posted on www.tib.eu: 2024-01-23, Last updated: 2024-01-26 | ||
520 | |a Provided herein is a leukocyte tyrosine kinase (LTK) inhibitor for use in the treatment of a viral infection in a subject, wherein the viral infection is caused by an RNA virus. Also provided are methods of treating a viral infection in a subject, wherein the viral infection is caused by an RNA virus, the method comprising administering to the subject an LTK inhibitor, and the use of an LTK inhibitor in the manufacture of a medicament for the treatment of a viral infection, wherein the viral infection is caused by an RNA virus. In particular, the infection may be an influenza or coronavirus infection in a human subject. | ||
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a MUNTHE LUDVIG |4 aut | |
700 | 0 | |a GRØDELAND GUNNVEIG |4 aut | |
700 | 0 | |a ROSENDAL KEN |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 09. Aug. |
773 | 1 | 8 | |g year:2023 |g day:09 |g month:08 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/73223829/publication/EP4221706A1?q=EP4221706 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2023 |b 09 |c 08 |
951 | |a AR | ||
952 | |j 2023 |b 09 |c 08 |